SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer
SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer
复制标题
DOI：
10.1002/jso.23975
复制
发表时间：
2015-08-01
影响因子：
2.5
通讯作者：
Kuwano, Hiroyuki
中科院分区：
文献类型：
--
作者：
Azuma, Yoko;Yokobori, Takehiko;Kuwano, Hiroyuki
BackgroundDespite advances in the development of various therapeutic agents, non-small cell lung cancer (NSCLC) is associated with a poor prognosis. To improve the prognosis of patients with NSCLC, new therapeutic targets for overcoming drug resistance are required. The process of autophagy is required to support the tumorigenesis and drug resistance of cancer cells. We investigated the clinical significance of SIRT6, a member of the NAD(+)-dependent deacetylase family, which regulates a variety of cancer-related processes, including autophagy.MethodsImmunohistochemistry analysis of SIRT6 expression and localization in 98 NSCLC clinical specimens and in vitro analysis using SIRT6-knockout lung carcinoma cell lines were performed.ResultsPatients with high cytoplasmic expression and low nuclear expression of SIRT6 (n=33) had more aggressive cancer, shorter overall survival, and shorter recurrence-free survival than did patients with different SIRT6 expression profiles (P
